# NCT03765918 (NCT03765918)

> Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03765918
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Head and Neck Neoplasms
- Interventions: Pembrolizumab 200 mg; Radiotherapy 60 Gray; Radiotherapy 66 Gray; Radiotherapy 70 Gray; Cisplatin 100 mg/m^2
- Enrollment: 714
- Primary outcome: Event-free Survival (EFS)
- Primary outcome: EFS in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10
- Primary outcome: EFS in Participants With PD-L1 CPS ≥1

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03765918